This paper demonstrates the efficacy of immunoproteasome inhibitor ONX-0914 in B-ALL cells bearing the MLL–AF4 translocations in vivo and in vitro, and in T-ALL cells. The gene discussed is KMT2A; the disease is acute lymphoblastic leukemia.